Incorporating Glucagon-Like Peptide-1 Receptor Agonists in the Individualized Management of Patients with Type 2 Diabetes

Incorporating Glucagon-Like Peptide-1 Receptor Agonists in the Individualized Management of Patients with Type 2 Diabetes

Release Date: March 29, 2019

Last Reviewed: March 23, 2019

Expiration Date: March 29, 2020

Time to Complete Activity: 1.0 hour

*This activity expired for credit on March 29, 2020 and is no longer available for credit

Faculty

Vivian Fonseca, MD

Professor of Medicine and Pharmacology

Tullis-Tulane Alumni Chair in Diabetes

Chief, Section of Endocrinology

Tulane University Health Sciences Center

New Orleans, LA

Steering Committee

Jeff Unger, MD, FAAFP, FACE

Assistant Clinical Professor of Family Medicine

UC Riverside School of Medicine

Director, Unger Concierge Primary Care Medical Group

Rancho Cucamonga, CA

Vivian Fonseca, MD

Professor of Medicine and Pharmacology

Tullis-Tulane Alumni Chair in Diabetes

Chief, Section of Endocrinology

Tulane University Health Sciences Center

New Orleans, LA

This activity is provided by Paradigm Medical Communications, LLC.

Target Audience

This activity has been designed to address the educational needs of family practice and other primary care clinicians involved in the management of patients with type 2 diabetes (T2D).

Statement of Need

With the advent of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), we have entered a new era of T2D treatment. These antidiabetic agents lower plasma glucose levels, and recent data show that some of them decrease the risk of macrovascular events. Guidelines have evolved that direct clinicians to use GLP-RAs earlier to maximize their benefit. Family practice clinicians, at the forefront of primary care, need to be up to date on the pharmacology of newer GLP-1 RAs, how to distinguish among available and emerging agents within the class, which patients will most benefit from GLP-1 RAs, and how to best incorporate them into patient management plans.

Learning Objectives

Upon proper completion of this activity, participants should be better able to:

Describe the mechanisms of action by which current and emerging GLP-1 RAs exert beneficial glycemic and extraglycemic effects on patients with T2D.
Match current and emerging GLP-1 RAs with appropriate patients based on unique agent characteristics (eg, dosing strategies, efficacy, and safety), current guideline recommendations, patient clinical characteristics, and patient preferences.
Describe clinician–patient communication strategies for promoting patient adherence to T2D treatment plans that include injectable therapies.

Physician Accreditation Statement

Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation Statement

Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Education

PAs may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

AAFP Credit
This Enduring Material activity, Incorporating Glucagon-Like Peptide-1 Receptor Agonists in the Individualized Management of Patients with Type 2 Diabetes, has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 03/29/2019. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Commercial Support

This activity is supported by an educational grant from Lilly.

Instructions for Participation

To receive a CME certificate of participation, you should:

Follow instructions to register or log in with your professional information and complete the pretest
View the online activity in its entirety
Complete and submit the online posttest and evaluation

A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.

There is no fee required for participation in this activity.

Hardware/Software Requirements

This certified CME activity is designed using HTML5 audio.

Supported Browsers:

For desktops (Windows/Mac)

Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher

For Tablets (iPad/Android/Surface)

iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher

Technical Support: If you have any technical problems or playback issues, please email us at contactus@paradigmmc.com.

Disclosures

In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.

Faculty/Steering Committee

Jeff Unger, MD, FAAFP, FACE

Consulting Fees: Abbott Laboratories; Janssen Pharmaceuticals, Inc; Novo Nordisk, Inc

Speaker Bureau: Janssen Pharmaceuticals, Inc; Novo Nordisk, Inc

Contracted Research: Janssen Pharmaceuticals, Inc; Novo Nordisk, Inc; Mylan NV; sanofi-aventis U.S. LLC

Ownership Interest: Novo Nordisk, Inc

Royalty: Lippincott Williams & Wilkins

Vivian Fonseca, MD
Contracted Research: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc
Consulting Fees: Asahi Kasei Pharma Corporation; AstraZeneca; Eli Lilly and Company; Intarcia Therapeutics, Inc; Novo Nordisk Inc; sanofi-aventis U.S. LLC; Takeda Pharmaceutical Company Ltd

Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.

Peer reviewer, Carol Levy, MD, CDE, has the following relationships to disclose:

Retained Consultant: sanofi-aventis U.S. LLC

Resolution of Conflict of Interest

Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.

Disclaimer

This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

Terms of Use and Privacy Policy

Disclaimer

The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the faculty, and do not necessarily represent those of Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm. Paradigm accepts no liability for the content referenced in this activity.

Paradigm Medical Communications, LLC is committed to protecting the privacy of those who participate in the activities (herein referred to as “website”) located at www.paradigmmc.com. The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information

This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information

The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm will not otherwise disclose personal information unless required to in a legal process. Paradigm staff members review individual test results to the extent necessary to record and track participants’ credits.

Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com.